Increasing investments in research and development activities are expected to drive market expansion shortly at a CAGR of 8.60% during the forecast period 2024 to 2032

Market Research Future (MRFR) has published a cooked research report on the “Mononucleosis Diagnostic Market” that contains information from 2019 to 2032. The Mononucleosis Diagnostic Market is estimated to register a CAGR of 8.60% during the forecast period of 2024 to 2032.

MRFR recognizes the following companies as the key players in the global Mononucleosis Diagnostic Market — Abbott (U.S.), DAIICHI SANKYO COMPANY, LIMITED (Japan), Weizmann Institute of Science (Israel), Biotest AG (Germany), Bio-Rad Laboratories, Inc. (U.S.), Genzyme (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Johnson & Johnson Services, Inc. (U.S.), BD (U.S.), DiaSorin Molecular LLC (U.S.)

Market Highlights

The global Mononucleosis Diagnostic Market is accounted to register a CAGR of 8.60% during the forecast period and is estimated to reach USD 3.28 billion by 2032.

Market expansion is propelled by the increasing demand for accurate and early diagnosis of mononucleosis to mitigate complications and guarantee efficient treatment. Moreover, the rising awareness among patients and healthcare providers regarding the significance of early detection and treatment of infectious illnesses is also fostering market growth.

Segment Analysis

The global Mononucleosis Diagnostic Market has been segmented based on Test Type and End-User.

Based on the Test Type, the market is segmented into Epstein Barr Virus (EBV) Antibody Test, Monospot Test, and Complete Blood Count Test. The Monospot Test segment was attributed to holding the largest market share in 2023. Monospot test is a latex agglutination test with equine erythrocytes as a primary substrate that ensures specific anti-EBV heterophile mucosal antibodies that are produced by the host immune system in response to EBV infection. The overall largest amount of demand is predicted to come from this test because of the advantages comprised of it, which include not interfering with other tests, highly accurate results with detection being quickly done, and affordability. On the other hand, in an article published in StatPearls in August 2021, they said that the mono spot test or heterophile antibody test with over 90% specificity is performed to diagnose mono. They provide a sensitivity closer to 85 percent. These studies make such a huge appeal to those on the market that the acceptance of monospot-type tests increases, and therefore, the segment is growing up.

Based on the End-User, the Mononucleosis Diagnostic Market has been segmented into Hospitals, Laboratories, and Others. The Hospitals segment was expected to hold the largest market share in 2023 due to the provision of excellent diagnostic tests, advanced image technology, and the staffing of highly qualified personnel who are highly skilled. On the other hand, hospitals possess the latest technological tools and highly specific departments that can quickly and accurately diagnose any disease of the human body.

Explore In-depth Market Details [Table of Content, List of Figures, List of Tables] of Mononucleosis Diagnostic Market Research Report

Regional Analysis

The global Mononucleosis Diagnostic Market, based on region, has been divided into North America, Europe, Asia-Pacific, and Rest of the World. North America consists of the US and Canada. The European mononucleosis Diagnostic Market comprises of Germany, France, the UK, Italy, Spain, and the rest of Europe. The Mononucleosis Diagnostic Market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World Mononucleosis Diagnostic Market comprises the Middle East, Africa, and Latin America.

The largest market share for the Mononucleosis Diagnostic Market was maintained by the North American regional sector. Developing a strong healthcare infrastructure with appropriate reimbursement policies supported by the increasing frequency of infectious mononucleosis (IM), innovation in healthcare infrastructure platforms supporting approved testing, and an intensified research and development process by key players in this region largely contributes to North America's leadership of the mononucleosis mission market. Roughly 125,000 cases of EBV are recorded every year, and EBV is thought to be behind 90% of these cases. As high as one-fourth to half of the preschool-aged children from the low social class in the USA will have encountered EBV by the age of 4. Aside from this, almost 3 out of 4 youths will be diagnosed with mono their first time having an EB virus.

Moreover, the Europe market has been persistently growing over the forecast period. Europe has a strong healthcare system that attracts a huge financial input in modern treatment facilities, equipment, and technology. In the year 2022, social outlay sickness and healthcare expenditure measured in terms of percent of the GDP is 8.1% at the EU level, showing a decrease in terms of percentage (PP) of 0.4 pp compared with 2021 (8.5%). Among the 24 EU countries for which 2022 estimates are available, social protection sickness and healthcare expenditure was highest in France (10.0% of GDP), Germany (9.7%), Slovenia (8.6%), Austria (8.5%) and Belgium (7.8%), while it was lowest in Bulgaria (4.2%), Ireland (4.6%), Hungary, Lithuania (both 4.7%) and Estonia (4.8%). Expansive healthcare became a way for systematic testing to diagnose the disease of mononucleosis, which in turn was responsible for the market growth.

The growing number of adolescents in the Asia Pacific region to which EBV infection is susceptible is one of the major motive factors considered and anticipated to push the market growth in the contemplated period. For instance, according to a Lancet utterance published in February 2022, mononucleosis is the main disorder among teenagers, and it is caused by the Epstein-Barr virus transmission. However, this virus is highly prevalent, with two maximum occurrence peaks in an individual's life: on the other hand, at around 3 to 4 years of age and the last one at 15 years of age. The cases of Epstein-Barr infection in childhood have a low risk of causing mononucleosis; however, a child who reaches adolescence increases the risk of such viral infection. That is to say, a large population of unbeknownst people has the Epstein-Barr virus.

Furthermore, the rest of the world's Mononucleosis Diagnostic Market is divided into the Middle East, Africa, and Latin America. These regions' economic growth has increased investments in healthcare infrastructure and related expenses. With US$161 billion in healthcare spending or 9.47% of GDP, Brazil has the largest healthcare market in Latin America. Of Brazil's 7,191 hospitals, 62% are private, according to the Brazilian Federation of Hospitals (FBH) and the National Confederation of Health (CNSaúde). More funding is being provided by public and private healthcare sectors to enhance the provision of healthcare, particularly diagnostics. This investment enhances access to testing facilities and technologies, which in turn helps the mononucleosis diagnostic market grow.

Key Findings of the Study

• The global Mononucleosis Diagnostic Market is expected to reach USD 3.28 billion by 2032, at a CAGR of 8.60% during the forecast period.


• The Asia-Pacific region accounted for the fastest-growing global market because of the growing adolescent population and the increased incidence of infectious mononucleosis (IM).


• Based on test type, the monospot test segment was attributed to holding the largest market in 2023, with an approximate market share of 55–60%


• Abbott (U.S.), DAIICHI SANKYO COMPANY, LIMITED (Japan), Weizmann Institute of Science (Israel), Biotest AG (Germany), Bio-Rad Laboratories, Inc. (U.S.), Genzyme (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Johnson & Johnson Services, Inc. (U.S.), BD (U.S.) and DiaSorin Molecular LLC (U.S.) are the key market players.